慢性HBV感染免疫耐受期患者应选择性进行抗病毒治疗

基金项目:

“十三五”国家科技重大专项课题 (2017ZX10302201-004-003);

“十三五”国家科技重大专项课题 (2017ZX10202201);

“十三五”国家科技重大专项课题 (2017ZX10201021-001-008);

首都卫生发展科研专项项目 (2020-1-2181);

青海省重点研发与转化计划 (2017-SF-159)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：陈新月负责整体思路和修改文章关键内容; 宋爱心负责起草文章。

详细信息

Antiviral therapy should be selected for patients in the immune-tolerant phase of chronic hepatitis B virus infection

First Department of Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[2]	LEE HW, CHAN HL. Unresolved issues of immune tolerance in chronic hepatitis B[J]. J Gastroenterol, 2020, 55(4): 383-389. DOI: 10.1007/s00535-020-01665-z.
[3]	CHEN CF, LEE WC, YANG HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma[J]. Gastroenterology, 2011, 141(4): 1240-1248, 1248. e1-2. DOI: 10.1053/j.gastro.2011.06.036.
[4]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[5]	CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A nationwide, multicenter, retrospective study[J]. J Infect Dis, 2017, 216(11): 1407-1414. DOI: 10.1093/infdis/jix506.
[6]	CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.